Hoda E. Sayegh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hoda E. Sayegh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Caleb Hearn
The Parity Center, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 19104 , United States
1 shared publication - Deborah Blythe Doroshow
Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY
1 shared publication Elena Baldwin
Icahn School of Medicine at Mount Sinai, New York, NY
1 shared publication- Elizabeth Prsic
Yale School of Medicine, Yale University, New Haven, Connecticut, USA
1 shared publication - Fauzia Riaz
James C. Dickerson, MD, MS, Jennifer L. Caswell-Jin, MD, and Fauzia Riaz, MD, MHS, Department of Medicine (Hematology and Oncology), Stanford University, Stanford, CA; and Jeremy D. Goldhaber-Fiebert, PhD, and Fernando Alarid-Escudero, PhD, Department of Health Policy, Stanford University, Stanford, CA
1 shared publication - Huili Zhu
Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX
1 shared publication
Latest Publications
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (8) , 1165-1173
Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized the care of patients with cancer, but use among hospitalized patients is controversial as a result of questionable benefit and high costs. To evaluate the role of ICIs in the inpatient (IP) setting, we conducted the Inpatient Immunotherapy Outcomes Study (IIOS) to describe characteristics and outcomes of patients who received IP ICIs. METHODS: IIOS is a retrospective study of patients treated with ICIs during hospitalization between 2012 and 2021 at five academic institutions. Data collection was performed using each institution's electronic medical record. We estimated overall survival (OS) from the first administration of ICI using the Kaplan-Meier method and used adjusted Cox proportional hazards models to explore associations between clinicodemographic variables and OS. RESULTS: Two hundred fifteen patients received IP ICIs (median age 60 years; 55% White; 14% Black; 13% Hispanic). Thoracic and head and neck (24%), GI (21%), and hematologic (19%) malignancies were most common. Most of the patients were ICI-naïve (75%), had stage IV solid malignancies (75%) at the time of IP ICI initiation, and had no radiographic response to ICI therapy (88%). Median OS from the first IP ICI dose was 1.55 months (95% CI, 1.08 to 1.81) for all patients and 1.28 months (95% CI, 0.95 to 1.80) for patients with advanced solid malignancies. Multivariable Cox proportional hazards model analysis found no clinicodemographic variables associated with improved OS after IP ICI administration. CONCLUSION: IIOS is the largest multi-institutional effort to describe outcomes after IP ICI administration. Clinical outcomes are poor after IP ICI use and IP ICIs should be used with caution.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (8) , 1165-1173
Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized the care of patients with cancer, but use among hospitalized patients is controversial as a result of questionable benefit and high costs. To evaluate the role of ICIs in the inpatient (IP) setting, we conducted the Inpatient Immunotherapy Outcomes Study (IIOS) to describe characteristics and outcomes of patients who received IP ICIs. METHODS: IIOS is a retrospective study of patients treated with ICIs during hospitalization between 2012 and 2021 at five academic institutions. Data collection was performed using each institution's electronic medical record. We estimated overall survival (OS) from the first administration of ICI using the Kaplan-Meier method and used adjusted Cox proportional hazards models to explore associations between clinicodemographic variables and OS. RESULTS: Two hundred fifteen patients received IP ICIs (median age 60 years; 55% White; 14% Black; 13% Hispanic). Thoracic and head and neck (24%), GI (21%), and hematologic (19%) malignancies were most common. Most of the patients were ICI-naïve (75%), had stage IV solid malignancies (75%) at the time of IP ICI initiation, and had no radiographic response to ICI therapy (88%). Median OS from the first IP ICI dose was 1.55 months (95% CI, 1.08 to 1.81) for all patients and 1.28 months (95% CI, 0.95 to 1.80) for patients with advanced solid malignancies. Multivariable Cox proportional hazards model analysis found no clinicodemographic variables associated with improved OS after IP ICI administration. CONCLUSION: IIOS is the largest multi-institutional effort to describe outcomes after IP ICI administration. Clinical outcomes are poor after IP ICI use and IP ICIs should be used with caution.